mounjaro retatrutide vs Retatrutide vs Mounjaro: Which is

Early studies suggest it may help stimulate dormant follicles to re-enter the growth phase

Retatrutide is the injectable triple agonist that hits GLP-1, GIP, and glucagon receptors at once, and it reached up to 24.2 percent average body weight loss in its Phase 2 obesity trial

Our weight loss program in California uses GLP-1 medications including Ozempic, Mounjaro, Wegovy, Zepbound, and more to help patients lose weight and reach their goals under the guidance of a licensed provider

In this trial, no differences in bodyweight changes or glucose control among treatments were observed ( vs liraglutide (mean dose = 1.3 mg/day) showed similar glycemic control and decrease of hepatic fat burden, although a reduction in BMI was only observed in the liraglutide-treated patients ( Semaglutide An ongoing phase 2 trial (NCT02970942) is currently investigating the efficacy and safety of three doses of subcutaneous semaglutide once-daily versus placebo in subjects with NASH

Mechanistic Insight: The Signaling That Drives Telogen Effluvium Hair follicles continuously interpret systemic signals